24.50
price down icon1.07%   -0.27
 
loading
전일 마감가:
$24.77
열려 있는:
$24.78
하루 거래량:
26.86M
Relative Volume:
0.56
시가총액:
$139.30B
수익:
$63.83B
순이익/손실:
$10.77B
주가수익비율:
13.03
EPS:
1.8799
순현금흐름:
$12.44B
1주 성능:
-1.39%
1개월 성능:
+3.14%
6개월 성능:
+6.31%
1년 성능:
-15.09%
1일 변동 폭
Value
$24.50
$24.78
1주일 범위
Value
$24.50
$24.93
52주 변동 폭
Value
$20.91
$29.17

화이자 Stock (PFE) Company Profile

Name
명칭
Pfizer Inc
Name
전화
(212) 733-2323
Name
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
직원
81,000
Name
트위터
@Pfizer
Name
다음 수익 날짜
2025-02-04
Name
최신 SEC 제출 서류
Name
PFE's Discussions on Twitter

PFE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
PFE
Pfizer Inc
24.50 140.83B 63.83B 10.77B 12.44B 1.8799
Drug Manufacturers - General icon
LLY
Lilly Eli Co
814.22 740.84B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
187.13 458.49B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.23 402.83B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
123.73 250.00B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.07 219.80B 63.43B 16.42B 14.72B 6.4861

화이자 Stock (PFE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-22 개시 Cantor Fitzgerald Neutral
2024-12-10 재개 BofA Securities Neutral
2024-11-15 개시 Wolfe Research Underperform
2024-10-25 재개 Citigroup Neutral
2024-10-17 개시 Bernstein Mkt Perform
2024-08-07 업그레이드 Daiwa Securities Neutral → Outperform
2024-03-22 다운그레이드 Argus Buy → Hold
2024-02-23 개시 Guggenheim Buy
2024-01-04 다운그레이드 TD Cowen Outperform → Market Perform
2023-10-20 재개 UBS Neutral
2023-10-16 업그레이드 Jefferies Hold → Buy
2023-07-17 재확인 JP Morgan Neutral
2023-07-14 개시 HSBC Securities Buy
2023-06-29 다운그레이드 Credit Suisse Outperform → Neutral
2023-05-11 다운그레이드 Daiwa Securities Outperform → Neutral
2023-03-06 개시 Jefferies Hold
2023-02-07 업그레이드 Daiwa Securities Neutral → Outperform
2023-01-26 다운그레이드 UBS Buy → Neutral
2023-01-17 다운그레이드 Wells Fargo Overweight → Equal Weight
2023-01-04 다운그레이드 BofA Securities Buy → Neutral
2022-12-13 업그레이드 Goldman Neutral → Buy
2022-11-18 개시 Credit Suisse Outperform
2022-05-23 개시 SVB Leerink Mkt Perform
2022-04-06 재개 Morgan Stanley Equal-Weight
2022-01-05 업그레이드 BofA Securities Neutral → Buy
2022-01-03 재확인 Bernstein Mkt Perform
2021-12-20 재확인 Cowen Outperform
2021-12-17 개시 Goldman Neutral
2021-12-13 업그레이드 UBS Neutral → Buy
2021-12-09 개시 Wells Fargo Overweight
2021-11-19 개시 BMO Capital Markets Outperform
2021-07-27 재개 Truist Buy
2021-05-06 다운그레이드 Mizuho Buy → Neutral
2021-04-07 재개 RBC Capital Mkts Sector Perform
2021-02-04 업그레이드 DZ Bank Hold → Buy
2020-12-16 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2020-11-19 재개 Goldman Neutral
2020-11-10 재개 Bernstein Mkt Perform
2020-10-12 다운그레이드 Atlantic Equities Overweight → Neutral
2020-09-29 개시 Berenberg Hold
2020-06-16 개시 SVB Leerink Mkt Perform
2020-02-27 개시 Barclays Equal Weight
2020-02-27 업그레이드 Standpoint Research Hold → Buy
2020-02-06 개시 Mizuho Buy
2020-01-07 개시 RBC Capital Mkts Outperform
2019-10-17 재개 BofA/Merrill Neutral
2019-07-30 다운그레이드 BofA/Merrill Buy → Neutral
2019-07-30 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2019-06-04 재개 Morgan Stanley Overweight
2019-02-20 재개 Citigroup Neutral
2019-01-31 업그레이드 Argus Hold → Buy
2019-01-31 업그레이드 Credit Suisse Neutral → Outperform
2019-01-23 다운그레이드 UBS Buy → Neutral
2018-12-11 다운그레이드 JP Morgan Overweight → Neutral
2018-11-01 다운그레이드 BMO Capital Markets Outperform → Market Perform
모두보기

화이자 주식(PFE)의 최신 뉴스

pulisher
08:40 AM

Eye Health Supplements Market Is Booming Worldwide 2025-2032 | - openPR.com

08:40 AM
pulisher
08:39 AM

Pfizer Whistleblower's Story Unveiled: Becky McClain's "Exposed" Memoir Hits Shelves October 28 - PR Newswire

08:39 AM
pulisher
06:51 AM

United States Adult Vaccine Market Research and Company Analysis Report 2025-2033 Featuring GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, and CSL Limited - Yahoo Finance

06:51 AM
pulisher
Oct 27, 2025

Will Pfizer Inc. stock benefit from sector rotationDollar Strength & Weekly Market Pulse Updates - Fundação Cultural do Pará

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Latest Clinical Trial: A New Hope for Prostate Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Pediatric Migraine Study: A Potential Game-Changer for Rimegepant - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on Ritlecitinib: A Potential Game-Changer for Chronic Urticaria? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Promising Phase 3 Study on Prostate Cancer Treatment: A Market Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Pediatric Migraine Study: A Potential Game-Changer in Migraine Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game Changer for Pregnant Women - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game Changer - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Ponsegromab Study: A Potential Game-Changer in Pancreatic Cancer Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Promising Phase 3 Study on Menstrual Migraine Prevention with Rimegepant - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s BEATRIX Study: A New Frontier in Maternal and Infant Health - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Elranatamab Study: A New Chapter in Multiple Myeloma Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Phase 3 Study on Elranatamab for Multiple Myeloma: A Potential Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Pediatric Migraine Study: A Potential Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Promising Migraine Study: A Potential Game-Changer for Adolescents - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on Zavicefta: A Potential Game-Changer in Infection Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Phase 3 Study on PF-06823859: A Potential Game-Changer for Myositis Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on PF-07934040: A Potential Game-Changer in Cancer Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer and Genmab’s Tivdak Study: Ocular Side Effects Under the Microscope - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Promising Trial for Multiple Myeloma: A Potential Game-Changer - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Abrocitinib Study: A Real-World Look at Treating Atopic Dermatitis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Somatrogon Study: A New Hope for Pediatric Growth Hormone Deficiency - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Latest Clinical Study: Exploring Carbamazepine’s Impact on PF-07248144 - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Promising Phase 1 Study on PF-07799933 for Advanced Tumors - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Promising Phase 3 Study on Ritlecitinib for Severe Alopecia Areata in Children - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Prostate Cancer Study: Long-term Safety and Market Impact - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Bladder Cancer Study: A Potential Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Xeljanz XR Study: A Closer Look at Safety and Effectiveness - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Promising Atopic Dermatitis Study: A Potential Game-Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on PF-07258669: A Potential Game-Changer for Elderly Nutrition - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Observational Study on TCR-MM in Italy: A Closer Look at Treatment Practices - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Phase 3 Study: A Potential Game-Changer in Breast Cancer Treatment? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Promising Pediatric Leukemia Study: A Potential Game Changer? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Phase 1 Study: A Potential Breakthrough for Kidney Disease Treatment - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on PF-07868489: A Potential Game-Changer for Pulmonary Arterial Hypertension? - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Prevenar 20 Study: A Key Step in Korean Market Expansion - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Zavicefta Study: A Strategic Move in the Korean Antibiotic Market - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on Rimegepant: What Investors Need to Know - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on Drug Interactions: What Investors Need to Know - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s E Coli Vaccine Study: A Promising Step in Infection Prevention - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Etrasimod Study: A Step Forward in Drug Safety for Breastfeeding Women - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s New Study on TUKYSA: What Investors Need to Know - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Pfizer’s Phase 3 Study on Ritlecitinib for Vitiligo: A Market Game-Changer? - TipRanks

Oct 27, 2025

화이자 (PFE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$118.25
price down icon 1.76%
drug_manufacturers_general SNY
$50.74
price down icon 1.34%
$290.48
price down icon 0.22%
drug_manufacturers_general NVO
$51.97
price down icon 1.73%
drug_manufacturers_general MRK
$87.04
price down icon 1.07%
자본화:     |  볼륨(24시간):